LINC00348: A Drug Target / Disease Biomarker (G100885781)

Target Name: LINC00348

NCBI ID: G100885781

LINC00348

Other Name(s): long intergenic non-protein coding RNA 348 | Long intergenic non-protein coding RNA 348

LINC00348: A Drug Target / Disease Biomarker

LINC00348 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the cell's intercellular signaling, which is crucial for various cellular processes such as cell growth, differentiation, and survival. LINC00348 is expressed in nearly all human tissues and has been associated with various diseases, including cancer, neurodegenerative diseases, and mental disorders.

The discovery and characterization of LINC00348 as a potential drug target and biomarker began with a screening experiment using a library of RNAi screening libraries. This screening approach led to the identification of a highly conserved gene that was enriched in RNAi-treated cells. The gene was then cloned and expressed in cell culture, and its function was confirmed by various bioassays, including RNA interference, luciferase assays, and mass spectrometry.

LINC00348 has been shown to play a crucial role in cell signaling by regulating the activity of several transcription factors, including NF-kappa-B, AP-1, and STAT3. It is a negative regulator of NF-kappa-B, which is a transcription factor that plays a role in cell signaling, inflammation, and survival. LINC00348 has been shown to physically interact with NF-kappa-B and to inhibit its activity, which suggests a potential therapeutic approach for treating neuroinflammatory diseases.

In addition to its role in cell signaling, LINC00348 has also been associated with various diseases and disorders. For example, it has been shown to be overexpressed in various cancer types, including breast, ovarian, and colorectal cancers. It has also been associated with neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. Additionally, LINC00348 has been shown to be involved in treating mental disorders, including depression and anxiety.

The potential therapeutic applications of LINC00348 are vast and continue to be explored. For example, it could be used as a target for small molecule inhibitors or RNAi-based therapies. Alternatively, it could be used as a biomarker for various diseases, including cancer, neurodegenerative diseases, and mental disorders.

In conclusion, LINC00348 is a promising drug target and biomarker that has the potential to treat a variety of diseases and disorders. Further research is needed to fully understand its function and develop effective therapies based on it.

Protein Name: Long Intergenic Non-protein Coding RNA 348

The "LINC00348 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00348 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets